Drug Information

Drug General Information
Drug ID
D0X8KC
Former ID
DNC000255
Drug Name
Arsenite
Drug Type
Small molecular drug
Indication Discovery agent Investigative [535043]
Formula
AsHO2
Canonical SMILES
O[As]=O
InChI
1S/AsHO2/c2-1-3/h(H,2,3)
InChIKey
XHTRYVMKFMUJLU-UHFFFAOYSA-N
CAS Number
CAS 10102-53-1
PubChem Compound ID
24577
PubChem Substance ID
623501, 5341080, 8167965, 24705099, 29291640, 50167595, 104360014, 135022021, 137133115, 242502173
ChEBI ID
ChEBI:29866
SuperDrug ATC ID
L01XX27
SuperDrug CAS ID
cas=001327533
Target and Pathway
Target(s) Inhibitor of nuclear factor kappa-B kinase Target Info Inhibitor [535043]
PathWhiz Pathway Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
Reactome Activation of NF-kappaB in B cells
NOD1/2 Signaling Pathway
RIP-mediated NFkB activation via ZBP1
AKT phosphorylates targets in the cytosol
p75NTR recruits signalling complexes
NF-kB is activated and signals survival
FCERI mediated NF-kB activation
Interleukin-1 signaling
Regulation of TNFR1 signaling
TNFR1-induced NFkappaB signaling pathway
IKBKB deficiency causes SCID
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
IkBA variant leads to EDA-ID
Dectin-1 mediated noncanonical NF-kB signaling
CLEC7A (Dectin-1) signaling
Constitutive Signaling by AKT1 E17K in Cancer
NIK-->noncanonical NF-kB signaling
MAP3K8 (TPL2)-dependent MAPK1/3 activation
TRAF6 mediated IRF7 activation
TRAF6 mediated NF-kB activation
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
Negative regulators of RIG-I/MDA5 signaling
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
IRAK1 recruits IKK complex
IKK complex recruitment mediated by RIP1
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
WikiPathways Toll-like receptor signaling pathway
Estrogen signaling pathway
TCR Signaling Pathway
Insulin Signaling
IL-4 Signaling Pathway
MAPK Signaling Pathway
NLR Proteins
Hair Follicle Development: Induction (Part 1 of 3)
MyD88 cascade initiated on plasma membrane
Cardiac Hypertrophic Response
Cytosolic sensors of pathogen-associated DNA
MyD88 dependent cascade initiated on endosome
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
MyD88:Mal cascade initiated on plasma membrane
Fc epsilon receptor (FCERI) signaling
MyD88-independent cascade
Signaling by the B Cell Receptor (BCR)
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Structural Pathway of Interleukin 1 (IL-1)
EBV LMP1 signaling
Polycystic Kidney Disease Pathway
Apoptosis
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
BDNF signaling pathway
Interleukin-11 Signaling Pathway
AGE/RAGE pathway
TNF alpha Signaling Pathway
B Cell Receptor Signaling Pathway
IL17 signaling pathway
TWEAK Signaling Pathway
Leptin signaling pathway
RANKL/RANK Signaling Pathway
Signalling by NGF
IL-1 signaling pathway
TCR signaling
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
Interleukin-1 signaling
Apoptosis Modulation and Signaling
Type II diabetes mellitus
MicroRNAs in cardiomyocyte hypertrophy
Regulation of toll-like receptor signaling pathway
Osteopontin Signaling
NOD pathway
References
Ref 535043Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000 Nov 17;275(46):36062-6.
Ref 535043Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000 Nov 17;275(46):36062-6.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.